Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Novacta Biosystems

Explore full profile

Develops and markets drugs for the treatment of bacterial infections, especially those caused by drug resistant bacteria

Welwyn Garden City, United KingdomFounded 2003Biotech & Life Sciences
Valuation $100–250M Last recorded · 2009
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Novacta Biosystems and the history behind them.

About Novacta Biosystems

Novacta Biosystems is a biotechnology company that specializes in harnessing the specificity and efficiency of biological systems for various commercial applications. The company operates in the healthcare, food, cosmetic, and chemical industries, providing innovative products and services. Novacta's proprietary technology platform focuses on biosynthetic pathway engineering, biotransformations, and metabolite factories, which are crucial in drug discovery and other industrial applications. The company serves a diverse client base, including pharmaceutical companies, food manufacturers, and cosmetic producers. Novacta's business model revolves around leveraging its advanced technology and extensive industry experience to meet the commercial needs of its clients while also developing its own internal products. Revenue is generated through a combination of product sales, service contracts, and partnerships with other industry players.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2003
Headquarters
Welwyn Garden City, United Kingdom
Employees
2
Open positions
None listed
Dealroom signal
25.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Hard Tech, DT and LS, uk is8 life sciences, science-based
Business model
Manufacturing
Client focus
b2b
Links
WebsiteLinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Jul 2009 $17M $69M Esperante Ventures · Oxford Technology · Iceni Seedcorn Fund · Wellcome Trust —
EARLY VC✓Equity / VC Jan 2008 $4.6M $18M Wellcome Trust · Esperante Ventures · Oxford Technology · Celtic Pharma —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Novacta Biosystems website traffic

Latest recorded traffic for Novacta Biosystems is 120 monthly website visits, up 200% over the last three months. Novacta Biosystems's team grew 0% over the past year.

Latest monthly visits120 3-month web change+200% 1-year team growth0%
Monthly website visitsDec 2016–Apr 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Clock BioDecoding the genome to reverse cellular aging Cambridge, United Kingdom Operational 11 $9.3M $21M
ElaitraAI-powered tomosynthesis imaging software for breast cancer detection London, United Kingdom Operational
Ignota LabsUsing cutting-edge AI algorithms to predict toxic endpoints, earlier in the drug discovery process London, United Kingdom Operational
CellVoyantAn AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases Bristol, United Kingdom Operational
CardiaTecApplying artificial intelligence on large-scale human multiomic data to develop the next generation of cardiovascular disease targets Cambridge, United Kingdom Operational
Multiomic HealthAI-enabled precision medicine for metabolic syndrome-related conditions London, United Kingdom Operational
Relation TherapeuticsUsing machine learning to improve drug discovery London, United Kingdom Operational
BactobioLondon-based biotechnology company using breakthrough technologies in synthetic biology London, United Kingdom Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • Oxford Technology
  • Wellcome Trust
  • Esperante Ventures
  • Celtic Pharma

Series B and later1 investor entered at this stage

  • Iceni Seedcorn Fund

Talent

Book a demo to see the people
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇬🇧 United Kingdom · Welwyn Garden City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Novacta Biosystems on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Novacta Biosystems’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.